Mental health and quality of life in different obesity phenotypes: a systematic review

Behnaz Abiri¹, Farhad Hosseinpanah¹, Seyedshahab Banihashem², Seyed Ataollah Madinehzad¹ and Majid Valizadeh¹

Abstract
Objectives: It has been suggested that obesity phenotypes are related to mental health problems and health-related quality of life (HRQoL). However, there is no certain consensus. This systematic review aimed to evaluate the association between different obesity phenotypes with common psychiatric symptoms and HRQoL.

Methods: Electronic databases i.e. PubMed, Scopus, EMBASE, and google scholar were searched until September 2021, to identify studies that investigated associations between the obesity phenotypes with psychiatric symptoms and/or mental and physical HRQoL. Two researchers independently checked titles and abstracts, evaluated full-text studies, extracted data, and appraised their quality using the Newcastle–Ottawa Scale.

Results: Eighteen studies, with a total of 3,929,203 participants, were included. Of the studies included in this systematic review, 10 articles evaluated the association between obesity phenotypes and psychiatric symptoms, while six papers investigated the association between HRQoL and obesity phenotypes, and two studies assessed both. As a whole, the findings of these studies suggest that obese individuals with a favorable metabolic profile have a slightly higher risk of mental health problems and poor quality of life, however, the risk becomes larger when obesity is combined with an adverse metabolic profile. So, metabolically healthy obesity may not be a completely benign condition in relation to mental disorders and poor quality of life.

Conclusion: According to published research, obesity is likely to increase the risk of mental health problems and poor quality of life when metabolic disturbances are present.

Keywords: Obesity phenotype, Mental health, Health-related quality of life, Metabolic phenotype

Background
Obesity is a worldwide problem characterized by excess body fat accumulation; the incidence is on the rise [1]. Worldwide, the prevalence of overweight and obesity has doubled since 1980, and a third of the population is obese or overweight all over the world now [2]. Obesity is connected with cardiometabolic diseases, such as hypertension, diabetes mellitus, dyslipidemia, and cardiovascular diseases (CVDs) [1]. Additionally, the obesity-related insulin resistance and metabolic disturbances can have adverse effects on the cardiometabolic system, which may in turn influence mental health and health-related quality of life (HRQoL) [1].

Individuals with obesity do not always have metabolic abnormalities, and individuals in the normal weight range do not always have favourable metabolic responses [3]. Hence, it has been suggested that obesity phenotypes are classified based on metabolic state such as metabolically healthy but obese (MHO), metabolically abnormal but of normal weight (MANW), and metabolically unhealthy and obese (MUHO) [3].

The relationship between obesity phenotypes and quality of life (QoL) and mental health has been examined in
some literature [4–7]; but, QoL and mental health issues associated with obesity phenotypes have not been studied as thoroughly as physical difficulties [8]. Despite a previous meta-analysis of prospective studies suggesting that individuals with higher body mass index (BMI) have a greater chance of developing depression [9], some studies find no relationship between obesity and depression [10], and one study reported lower mental health risks associated with higher BMI [11]. The metabolic syndrome (MetS), on the other hand, leads to health conditions that are unfavourable; therefore, people with MetS tend to have lower overall health-related quality of life [12]. There is a discrepancy amongst findings of the unfavorable relationship between HRQoL and MetS, with some reporting a negative association between women [13–15], men [16], or reporting even better HRQoL amongst those with MetS [17] or no relationship at all [18, 19].

Yet, the impact of obesity phenotypes on QoL and mental health outcomes, including stress, anxiety, and depression, remains unclear. These conditions influence individuals’ moods or feelings, reduce productivity, and lead to an enormous economic burden [8].

It would be helpful to understand how metabolic phenotypes relate to mental health and HRQoL for individuals with MHO as well as those who present as MANW in terms of health promotion and policies. So, in this systematic review, we examine the relationship between obesity phenotypes with mental health and HRQoL.

**Methods**

**Search strategy**

The systematic review question was “what is the relationship between obesity phenotypes with common psychiatric symptoms and HRQoL?” A literature review was done in PubMed, Scopus, EMBASE, and google scholar databases until September 2021, with no restrictions on language and date. The following search terms were used in this search: metabolically AND (healthy OR unhealthy OR benign) AND (overweight OR obes* OR “over weight”) AND phenotype AND (depression OR depress* OR “depressive disorder” OR mood OR stress OR emotion OR anxiety OR mental health) AND (quality of life OR health-related quality of life). We searched keywords in PubMed using both [tiab] and [MeSH] tags. The reference lists of the retrieved papers were also scanned to ensure no data had been missed. To find relevant studies missed by the electronic search strategy, citation tracing for included studies was also performed. The citation tracing process lasted until September 2021. All potentially eligible studies were included in the review, regardless of primary outcome or language. All included articles were published in English. The selection process is presented in Fig. 1. Because of the diversity in the comparisons of the included studies (differences in outcomes, exposures, participants, and settings) and lack of data amenable to analysis and pooled size, we conducted a qualitative systematic review. The systematic review was carried out following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) Statement [20].

**Eligibility criteria**

Observational studies (cohort, cross-sectional, and case–control studies) were considered, and on the other hand, clinical trials, reviews, editorials, and studies on non-human models as well as studies without full text access were excluded. We did not specify a strict age range since the number of eligible studies was limited. The studies involved evaluating the association between different obesity phenotypes with mental health outcomes and QoL.

**Study selection**

Following the elimination of duplicates, titles and abstracts collected in the initial search were evaluated separately by two authors (BA and FH). Full-text articles were assessed by these two authors to be assured they matched the eligible inclusion and exclusion criteria. Researchers were consulted about any disagreements they had.

**Data extraction and quality assessment**

A data mining sheet was created to record information about: first author, year of publication, study design, number and characteristics of participants, exposure assessment, outcomes, and main findings. Details of data extraction and critical appraisal of the studies are demonstrated in Table 1. The Newcastle–Ottawa Scale (NOS) for evaluating quality of observational studies was used [21]. The scale contained eight items ranging from zero to nine, pertaining to evaluation of selection, comparability, and outcome or exposure. The quality assessment scores of articles are shown in Table 2.

**Results**

**Study characteristics**

Initially, 3980 studies were found from databases. Among which, after removing 1454 duplicate articles, 2073 were excluded after scanning the titles/abstracts because they did not relate to the present systematic review. After carefully screening of 453 full texts, we also excluded 435 more studies because they investigated the association between metabolic phenotype with an outcome other than mental health or HRQoL, or were animal or in vitro studies in design, editorial, and reviews. Finally,
18 different studies [1, 4–8, 12, 22–32] with a total of 3,929,203 participants, published between 2008 and 2021, were eligible for the systematic review. The flow chart of study selection is presented in Fig. 1.

The sample size of the included studies ranged between 101 and 3,586,492 subjects. The age of participants was ≥ 18 years old.

Among the included articles, all of the studies involved both sexes. Four studies were longitudinal [5, 25, 28, 30] and others were cross-sectional [1, 4, 6, 8, 12, 22–24, 26, 27, 29–32]. Table 1 summarizes the characteristics of all included studies.

Outcome assessment

Data obtained included 18 studies with 10 articles on mental health dimensions [7, 8, 23–30], six papers with data on health-related quality of life [4, 5, 12, 22, 31, 32] and two studies investigated both mental health and QoL in different metabolic phenotypes [1, 6]. Depression is the outcome in 8 studies [6, 7, 23, 25, 27–30] and was assessed by different tools: the Center for Epidemiologic Studies Depression scale (CES-D) in four studies [7, 28–30], Beck Depression Inventory (BDI) in two studies [6, 27], Geriatric Depression Scale (GDS) in one study [24], Montgomery-Asberg Depression Rating Scale (MADRS) and Mini-International Neuropsychiatric Interview (MINI) in another study [23], and International Classification of Disease (ICD-10) in one study [25]. In one paper [7] anxiety and well being were assessed by Hospital Anxiety and Depression Scale (HADS) and World Health Organization (WHO) well being index, respectively. In one study [8] emotion state was assessed using Depression, Anxiety, and Stress Scale-21 (DASS-21). Psychiatric symptoms were assessed by asking the related questions, in one study [1]. Quality of life is the outcome in eight studies [1, 4–6, 12, 22, 31, 32] and was assessed by different scales: the Short Form (SF-36 and SF-12) in six studies [4–6, 8, 22, 32], EuroQol-5 dimension questionnaire (EQ-5D) in two papers [1, 12], and Scottish health survey in one study [31].

The association between obesity phenotypes with mental health and HRQoL

In a study by Mehrabi et al. [8], between 2469 men and women it was demonstrated that after adjustment for probable confounders, compared to MHNW men, in metabolically unhealthy men, anxiety levels are significantly higher regardless of whether they are obese (OR 1.78, 95% CI 1.25–2.54; P ≤ 0.001) or not (OR 1.61, 95% CI 1.17–2.21; P ≤ 0.001), and also in MUHO women (OR 1.73, 95% CI 1.28–2.34; P ≤ 0.001) compared to MHNW women. Additionally, Men who are MUNOs are
| First author (Reference No) | Year of publication | Study design | No of participants (sex) | Age of participants | Exposure assessment | Outcome assessment | Main finding |
|-----------------------------|---------------------|--------------|--------------------------|--------------------|--------------------|-------------------|--------------|
| Mehrabi [8]                 | 2021                | Cross-sectional | 2469 (male and female)   | 46.2 ± 15.9        | Obesity was defined as BMI ≥ 30 kg/m², and MUH status based on having MetS or T2DM | Emotional states were assessed by the Persian version of DASS-21 | Men and women with various obesity phenotypes experienced different anxiety and stress levels. While MUHO women and all MUH men experienced more anxiety and stress levels than MHNO individuals, none of the obesity phenotypes were associated with depression |
| Portugal-Nunes [24]        | 2021                | Cross-sectional | 101 (male and female)    | 64 ± 8.46          | The anthropometric measures included weight (Kg), height (m), and abdominal perimeter (cm). FBG, fasting insulin, TG, and HDL were measured | Mood was assessed by the Geriatric Depression Scale (GDS, long-version) | The association of metabolic dysfunction with depressive mood is influenced by age |
| Park and Lee [29]          | 2021                | Cross-sectional | 288,044 (male and female)  | ≥ 18 years         | The MUH group was defined as those who have one of the following characteristics: FBG > 100 mg/dL or current use of hypoglycemic medication, BP ≥ 130/85 mmHg or current use of BP medication, TG ≥ 150 mg/dL, or the use of antilipidemic medication, low HDL-C (< 40 mg/dL for men and < 50 mg/dL for women), and HOMA-IR score ≥ 2.5. MH was defined as those who do not meet the above criteria | Depression was assessed by the CES-D scale | The metabolic phenotype exerts a direct influence on emotional problems. Metabolic health may be used as an indicator of mental health |
| Kim [1]                    | 2020                | Cross-sectional | 6057 (male and female)   | ≥ 20 years         | Normal weight or obese was assessed by BMI. MUH status was defined as the presence of any three or more of the revised NCEP-ATP III definitions of MetS | Psychiatric symptoms including sleep time, stress, depression, suicide thoughts, were assessed by asking the related questions. Health related quality of life was evaluated by the EQ-5D | With or without metabolic abnormalities, obesity is associated with mental health problems and decreased quality of life |
| First author (Reference No) | Year of publication | Study design | No of participants (sex) | Age of participants | Exposure assessment | Outcome assessment | Main finding |
|----------------------------|---------------------|--------------|--------------------------|---------------------|--------------------|-------------------|--------------|
| Seo [25]                   | 2020                | Longitudinal | 3,586,492 adult individuals (male and female) | 40–70 years         | Obesity was defined as BMI ≥ 25 kg/m² and MH as MetS risk <2 | Depression was determined by a recording of ICD-10 codes F32.0 to F34.9 on health insurance data or the taking of antidepressant | MUHO has a higher risk of depressive symptoms than MHN. Furthermore, in women participants, MHO is also related to a higher risk of depressive symptoms. MHO is not a totally benign condition in relation to depression in women |
| Imbiriba [26]             | 2020                | Cross-sectional | 2371 (male and female) | 49.6±7.1 years | Metabolic profile classification was based on the Third NHANES criteria for anthropometric–metabolic profiles | Mental health data were collected through the Portuguese version of the CIS-R | There was a significant association between low skill discretion and an adverse metabolic profile in models adjusted for age, sex and race. No associations were significant between job stress domains and the metabolic profile of obese individuals in full models |
| Delgado [23]              | 2018                | Cross-sectional | 125 (100 obese, 25 non-obese) (male and female) | Obese subjects: 39.5 (10.5) years Non-obese subjects: 39.9 (10.4) years | MUO was defined as obesity associated with two or more metabolic alterations, including low HDL, hypertriglyceridemia, high FBG and hypertension | Depression was assessed using the Montgomery-Asberg Depression Rating Scale (MADRS) and Mini-International Neuropsychiatric Interview (MINI) | Inclusion of inflammation in the definition of MUO drives the association found between poor metabolic health and depressive symptoms |
| Amiri [32]                | 2018                | Cross-sectional | 2880 (male and female) | >19 years | Weight status was assessed by BMI. Based on the JIS definition, metabolic syndrome is defined as the presence of any 3 of the following five risk factors: (1) abdominal obesity; (2) reduced HDL-C <45 mg/dl in women, <50 in men or on drug treatment; (3) high TG levels ≥ 150 mg/dl or on drug treatment; (4) high BP or drug treatment; (5) high FBG ≥ 100 mg/dl or on drug treatment | HRQoL was assessed using the Short Form 12-Item Health Survey version 2 (SF-12v2) | Compared to those with normal weight normal metabolic status, only obese dysmetabolic individuals were more likely to report poor physical HRQoL in both genders |
| First author (Reference No) | Year of publication | Study design | No of participants (sex) | Age of participants | Exposure assessment | Outcome assessment | Main finding |
|-----------------------------|---------------------|--------------|--------------------------|--------------------|--------------------|--------------------|--------------|
| Yosaee [27]                 | 2018                | Cross-sectional | 157 adult subjects (male and female) | 20–55 years | MUHO, MHO and non-obese metabolically healthy, diagnosed according to the NCEP-ATP III criteria and BMI | Depressive symptoms assessed by BDI | MHO was a benign phenotype in relation to depression |
| Truthmann [22]              | 2017                | Cross-sectional | 3298 subjects (male and female) | 18–79 years | MHNO, MUNO, MHO, and MUO were defined by ATPIII criteria and BMI | Physical HRQoL was measured by the Short Form-36 version 2 PCS score | Obesity was significantly related to lower physical HRQoL, independent of metabolic health status, especially among women |
| Hinnouho [30]               | 2017                | Longitudinal   | 14,475 subjects (male and female) | 44–59 years | Obesity was defined as BMI ≥ 30 kg/m² and metabolic health as having none of the self-reported following CV risk factors: hypertension, T2DM and dyslipidemia | Depressive symptoms were assessed by the Center For CES-D scale | Poor metabolic health, irrespective of BMI was associated with more depression at the baseline, whereas a poorer course of depression over time was observed only in those with both obesity and poor metabolic health |
| Lopez-Garcia [5]            | 2017                | Longitudinal   | 4397 individuals (male and female) | ≥ 18 years | Weight was assessed by BMI. Two metabolic statuses 9 were defined: healthy (0–1 CA) and unhealthy (≥ 2 CA) | HRQoL was measured with the PCS and the MCS of the SF-12 questionnaire | Both obesity and CA should be addressed to improve HRQoL |
| Donini [4]                  | 2016                | Cross-sectional | 253 subjects (male and female) | 18–65 years | MHO and MUO were defined based on the absence or the presence of the MetS, respectively. PA was assessed by IPAQ questionnaire | HRQoL was measured with the SF-12 questionnaire | The metabolic comorbidity and the impairment of functional ability and psycho-social functioning may have a different timing in the natural history of obesity |
| Yang [12]                   | 2016                | Cross-sectional | 6217 men and 8243 women | Over 30 years | Metabolic abnormality was defined by the criteria of the NCEP-ATP III | HRQoL was evaluated using the EQ-5D questionnaire | The MANW is the least favorable state of HRQoL for men. In women, the MUHO and MHO groups had the most adversely affected HRQoL |
Table 1 (continued)

| First author (Reference No) | Year of publication | Study design | No of participants (sex) | Age of participants | Exposure assessment | Outcome assessment | Main finding |
|-----------------------------|---------------------|--------------|--------------------------|---------------------|---------------------|------------------|-------------|
| Phillips and Perry [7]      | 2015                | Cross-sectional | 2047 middle-aged male and female | 50–69 years         | MH was defined by three definitions based on a range of CA including MetS criteria, insulin resistance and inflammation | Depression, anxiety and well-being were assessed using the CES-D, the HADS and the WHO-5 Well Being Index | A favourable metabolic profile is positively related to mental health in obese middle-aged adults, but findings were dependent on MH definition |
| Hamer [28]                  | 2012                | Longitudinal | 3851 subjects (male and female) | 63.0 ± 8.9 years    | Based on BP, HDL, TG, glycated haemoglobin, and CRP, subjects were classified as ‘MH’ (0 or 1 metabolic abnormality) or ‘MU’ (≥ 2 metabolic abnormalities) | Depressive symptoms were assessed using the 8-item CES-D scale | The association between obesity and risk of depressive symptoms seems to be partly dependent on metabolic health |
| Ul-Haq [31]                 | 2012                | Cross-sectional | 5608 subjects (male and female) | ≥ 20 years          | Metabolic comorbidity was defined as the presence of one or more of these conditions: diabetes, HTN, hypercholesterolemia or CVD | HRQoL was evaluated using the Scottish Health Survey | The adverse impact of obesity on HRQoL is greater among individuals with metabolic comorbidity |
| Tsai [6]                    | 2008                | Cross-sectional | 361 overweight and obese subjects (male and female) | No MetS: 44.9 ± 10.0 MetS: 48.2 ± 9.5 | The presence of MetS was assessed using the NCEP criteria | HRQoL was measured using the SF-36 questionnaire. Depression was assessed using the BDI | Individuals with MetS reported lower HRQoL. This appeared to be an effect of increased weight, rather than a unique effect of MetS |

BMI, body mass index; T2DM, type 2 diabetes mellitus; MetS, metabolic syndrome; MUH, metabolically unhealthy; MUHO, metabolically unhealthy obesity; DASS-21, depression, anxiety, and stress scale-21; MHNO, metabolically healthy non-obese; FBG, fasting blood glucose; TG, triglycerides; HDL, high-density lipoprotein; BP, blood pressure; MH, metabolically healthy; CES-D, Center for Epidemiologic studies depression; NCEP-ATP III, national cholesterol education program adult treatment panel; EQ-SD, EuroQol five-dimension; ICD, international classification of disease; NHANES, national health and nutrition examination survey; CIS-R, Clinical Interview Schedule-Revised; MUHO, metabolically unhealthy obesity; HRQoL, health related quality of life; BDI, beck depression inventory; PCS, physical component summary; CV, cardiovascular; CA, cardiometabolic abnormality; MCS, mental component summary; PA, physical activity; IPAQ, international physical activity questionnaire; HADS, hospital anxiety and depression scale; WHO, world health organization; MANW, metabolically abnormal but normal weight; CRP, C-reactive protein; MU, metabolically unhealthy; CVD, cardiovascular disease; HTN, hypertension; JIS, Joint Interim Statement.
significantly more likely to experience stress than those who are MHNWs (OR 1.40, 95% CI 1.02–1.90; $P = 0.04$), and women who are MUHO have significantly higher stress levels than those who are MHNW (OR 1.45, 95% CI 1.07–1.96; $P = 0.02$). Researchers found that mean anxiety scores in men and mean anxiety and stress scores in women were significantly different among obese phenotypes ($P = 0.044$, $P = 0.02$, and $P = 0.022$, respectively). After adjustment for probable confounders, such as age, marital state, education, job state, smoking state, and physical activity, the odds of having higher levels of anxiety were considerably greater in MUHO (OR 1.78, 95% CI 1.07–1.96; $P = 0.02$). Researchers found that mean anxiety scores in men and mean anxiety and stress scores in women were significantly different among obese phenotypes ($P = 0.044$, $P = 0.02$, and $P = 0.022$, respectively). After adjustment for probable confounders, such as age, marital state, education, job state, smoking state, and physical activity, the odds of having higher levels of anxiety were considerably greater in MUHO (OR 1.78, 95% CI 1.07–1.96; $P = 0.02$). Researchers found that mean anxiety scores in men and mean anxiety and stress scores in women were significantly different among obese phenotypes ($P = 0.044$, $P = 0.02$, and $P = 0.022$, respectively).

Another cross-sectional analysis [24] concluded that an abnormal glucose or lipid metabolism was linearly related to depressive symptoms, and excess weight was U-shaped in its relationship to depression. Glucose dysmetabolism, obesity, and metabolic disturbances are positively related to depression among the younger subjects in our sample and disappear with age. In the respective models, metabolic abnormalities ($\beta = 0.066$, $P = 0.029$), disturbances in glucose ($\beta = 0.062$, $P = 0.039$), and lipids metabolism ($\beta = 0.076$, $P = 0.011$) were significantly related to a greater score in GDS.

In a study [26] on 2371 obese individuals at the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), the findings after adjusting for race, age, and gender showed low skill discretion to be related to MUHO. But, in fully-adjusted models, the MUHO phenotype was not related to high job demand (OR = 1.05; 95% CI 0.82–1.35), low skill discretion (OR = 1.26; 95% CI 0.95–1.68), low decision power (OR = 0.94; 95% CI 0.70–1.25) nor low social support (OR = 0.93; 95% CI 0.71–1.20).

A comparison was made by Yosae et al. [27] between depressed MUHO and a healthy control group. The metabolically healthy obese and nonobese group had significantly lower BDI scores (OR = 0.93), low decis -

dy 05; 95% CI 0.61–0.98). Another research [28] revealed that MUHO subjects had a greater risk of depression in follow-up (OR = 1.50, 95% CI 1.05–2.15) than non-obese healthy subjects after adjustment for baseline CES-D scores and other variables, though the MHO did not. (OR = 1.50, 95% CI 0.663–0.993). Suicide risk was considerably higher among women over 40 years old in the metabolically unhealthy group when other covariates weren't adjusted (OR = 1.535,
Among men of all ages, there did not seem to be a significant difference in risk factors for suicide depending on metabolic health or unhealthy metabolism.

MUHO participants were more likely than MHNO participants to suffer from anxiety and depression, according to another cross-sectional study conducted on 2047 middle-aged Irish men and women. [7], demonstrated that compared to the MHNO participants the risk of anxiety and depression was higher in the MUHO group (OR 1.63–1.66, OR 1.82–1.83 for anxiety and depressive mood, respectively, according to the definition of metabolic health). MHO subjects did not appear to be at greater risk for these conditions.

Hinnouho et al. [30] in their investigation on a sample of 14,475 men and women, in the Gazel cohort, revealed that metabolically unhealthy normal weight [OR 1.37; 95% CI 1.25 ± 1.51], overweight [1.44 (1.31 ± 1.59)] and obese [1.30 (1.10 ± 1.54)] but not MHO subjects [1.04 (0.81 ± 1.32)] had more depression risk at the beginning of follow-up compared to MHNW groups.

In MHNW individuals, individual’s levels of depression declined over time [0.52 (0.50 ± 0.55)], whereas MUHO respondents were less affected [1.22 (1.07 ± 1.40)]. Participants in the MUHO study had a higher risk of depressive symptoms at the beginning of follow-up compared to those participating in MHO, but this risk declined over time as well.

In another cross-sectional survey [1] there was a tendency for QoL issues to increase from the MHNW to the MHO, metabolically unhealthy normal weight, and MUHO groups among 6057 Korean population members. There is an increase in the number of people with inadequate sleep times from the MHNW to the MUHO (P for trend = 0.015). MHO participants were more likely to experience stress than the other individuals (P = 0.013). Following adjustment for gender, age, smoking state, physical activity, alcohol consumption, household income, and history of comorbidities, the ORs for movability difficulties in the MHO and MUHO groups were 1.43 (95% CI 1.01–2.04) and 1.94 (95% CI 1.52–2.47), respectively. The adjusted ORs for difficulties with self-care and common activities in the MUHO group were 2.07 (95% CI 1.39–3.10) and 2.08 (95% CI 1.53–2.81), respectively. The adjusted ORs for pain and displeasure in the MHO and MUHO groups were 1.35 (95% CI 1.06–1.73) and 1.39 (95% CI 1.14–1.69), respectively. Regarding psychiatric symptoms, after adjustment for the probable confounders, the adjusted OR for insufficient sleep duration in the MUHO group was 1.25 (95% CI 1.04–1.50) and the adjusted ORs for stress in the MHO and MUHO groups were 1.27 (95% CI 1.05–1.54) and 1.33 (95% CI 1.11–1.60), respectively. After controlling for the confounders, the mean EQ-5D scale in the MHO and MUHO groups were significantly lower than that of the metabolically healthy normal weight group (1.032–0.101 and 1.023–0.101 vs. 1.042–0.097, P = 0.011 and < 0.001, respectively). However, metabolically unhealthy normal weight and MHNW groups did not differ in mean EQ-5D scores.

The study by Tasi et al. [6] found that those with overweight/obesity and MetS had significantly lower scores on two subscales of the SF-36 (short form-36). These subscales evaluated aspects of mental well-being or scored the mental component summary. These were general health (P = 0.007) and physical functioning (P = 0.021). No difference was found between individuals with and without MetS on any of the four subscales of the SF-36 that evaluates mental health aspects or the mental component summary score.

A cross-sectional data [22], in 6860 men and women, from the German Health Interview and Examination Survey 2008–11, it was shown that compared to MHNW, all obese subgroups with different metabolic health had considerably lower physical component summary (PCS) score in men and women. a reverse relationship with PCS was strongest for MUHO (men: −7.0 [−8.2; −5.8]; women: −9.6 [−10.2; −7.9]), intermediate for metabolically unhealthy non-obese (men: −4.2 [−5.3; −3.1]; women: −5.6 [−6.8; −4.4]) and least pronounced for MHO (men: −2.2 [−3.6; −0.8]; women −3.9 [−5.4; −2.5]). Following adjustment for covariates, the MHNW variation is statistically significant for all groups, but declines for metabolically unhealthy non-obese (men: −1.3 [−2.3; −0.3]; women: −1.5 [−2.7; −0.3].

According to another work [12] conducted over 30 years which involved 6217 men and 8243 women, those with metabolically unhealthy normal weights were consistently sicker on all aspects and had poorer HRQoL than normal weight men. But, no significant influence observed after adjustment for possible confounders. Most adversely affected were the MUHO women, followed by the MHO women. In the MUHO and MHO groups, the variables related to mobility and disturbed HRQoL were significant after adjustment for all confounders.

In a research, conducted by Ul-Haq et al. [31], revealed that as BMI increased, utility scores decreased in overweight/obese subjects with metabolic abnormalities (morbidly obese, adjusted coefficient: −0.064, 95% CI −0.115, −0.012, P = 0.015 for metabolic comorbidity vs. −0.042, 95% CI −0.067, −0.018, P = 0.001 for those without metabolic abnormality).

In another research [29] it was not observed any significant difference in HR-QoL between MHO and MUHO (SF-36 total score: 60 ± 20.8 vs. 62.8 ± 18.2, P = 0.27).
Lopez-Garcia et al. [5] stated that in comparison to MHNW subjects, the unhealthy normal-weight and the healthy overweight subjects had a similar PCS score; however, the PCS was lower among those with unhealthy overweight ($-1.79$; 95% CI $-2.66$ to $-0.94$), with MHO ($-1.45$; 95% CI $-2.67$ to $-0.24$) and unhealthy obesity ($-1.97$; 95% CI $-2.88$ to $-1.05$). Regardless of metabolic condition, overweight or obesity did not affect the Mental Component Summary score.

In another study [32] between 2880 healthy adults with age $>19$ years, Amiri et al. found that only physical aspects of HRQoL differ between obesity phenotypes, both in men and in women ($P < 0.05$). Additionally, following adjustment for marital state, age, job status, physical activity, and education, the likelihood of reporting poor physical HRQoL was considerably greater in both men (OR $2.887$, 95% CI $1.674$ to $4.977$; $P < 0.001$) and women (OR $2.887$, 95% CI $1.674$ to $4.977$; $P < 0.001$) with MUHO state, in comparison to MHNW individuals. However, with the exception of overweight women with normal metabolic state, who were less probably to have poor psychological wellbeing (OR $0.638$, 95% CI $0.415$ to $0.981$; $P < 0.05$), mental HRQoL was not associated with either phenotype regardless of gender.

**Discussion**

The current systematic review aimed to investigate mental health status and HRQoL in different obesity phenotypes. We found that when obesity coexists with metabolic disorders, its connection with mental health issues and poor QoL is more pronounced. However, in terms of mental disorders and poor quality of life, MHO is not fully benign.

As well as being associated with a variety of chronic diseases and metabolic disorders, obesity is also associated with one’s mental health and quality of life [1]. There are some bidirectional relationships between MetS and depressive symptoms [33], and diabetes and depressive mood [34], proposing that a number of pathways may be involved in the association between excessive weight, metabolic disturbances, and depression.

There have been similar findings in studies of Canadian women [35] and Mexican men [36], indicating that excess weight does not predict depression. Further, MetS has not been associated with depression in Turkish adults [37]. In a follow-up study of metabolic phenotype in depression with long-term duration, depression risk was initially higher in metabolically unhealthy individuals regardless of weight status; however, this finding was not significant in MHO groups [30]. Among adults with obesity, metabolically healthy individuals have lower rates of depression and anxiety, whereas metabolically unhealthy patients have higher rates of depression and anxiety [7]. Although a previous meta-analysis concluded that obesity is associated with an elevated depression risk [9], the evidence is contradictory [10, 11, 38]. In relation to depression in obesity phenotypes, numerous factors, including metabolic factors, need to be investigated. After controlling for covariates such as gender, age, marital status, and education, these results remained the same. Previously, the relationship between obesity phenotypes and depressive mood was shown to be mediated by waist circumference (WC) and fasting blood sugar [28, 39]. Understanding the relationship between depressive mood and obesity phenotypes will require a deeper description of other covariates such as adipokine.

Studies suggest that certain physiological mechanisms may explain the elevated depression risk in MUHO people. Hypothalamic–pituitary–adrenal (HPA) axis disruptions may lead to dysfunction of cortisol regulation, culminating in dysglycemia and insulin resistance, causing a cascade of events in the MetS [27]. Depression is linked to disruptions of the HPA axis [27]. Additionally, depressive mood may occur in adolescents with obesity due to biochemical changes caused by metabolic disturbances, including expanded cerebrospinal fluid space and diminished white matter volume [27]. Furthermore, neurodegeneration and structural remodeling may impair emotion, study and memory through brain inflammation [40], and mostly affected the hippocampus [40]. A major component of the MUHO definition consisted of inflammation in the majority of previous studies. Accordingly, inflammation is a likely factor that contributes to the association between MUHO and depression, and the role of inflammatory agents and metabolic disturbances will continue to be determined [23].

MetS and work-related stress were linked in a previous systematic review [41]. In a meta-analysis [33], it was concluded that MetS is a risk factor for depression, and depression is a risk factor for MetS, demonstrating a bidirectional relationship. Metabolic disturbances are a major component of MetS, and these disturbances may be causing depression through their interactions with MetS. When it comes to metabolic abnormalities and depression, age plays a major role in moderating the relationship. Various combinations of MetS components have different effects on mortality risk based on the age at which MetS presents and when the MetS component presents [42]. It is probable that metabolic dysfunction may also be linked to depression based on age differences in its manifestation. Further, the theory holds that a higher BMI may be indicative of greater physiologic and functional reserve (due to greater muscle mass), preventing depression later in life [43].

The main marker for MetS, insulin resistance derived from excess adiposity and persistent low-grade
inflammation, is more widely developed as a result of hypertension, dyslipidemia, and an inflammatory state [7]. Depressive disorders have been related to some MetS components, as well with disruptions of metabolic networks, like insulin-glucose homeostasis, inflammatory processes, and unhealthy lifestyle behaviors. [7, 9, 44–46]. According to an epidemiological study, depression is twofold more common among diabetic patients than in the general population, and diabetes increases the risk of depression by twofold [47]. This relationship has also been reported to be explained by the inefficient utilization of glucose caused by central insulin resistance in vulnerable brain regions (such as limbic system) in depressed patients [24]. In animal models, it has been shown that brain-specific knockout of insulin receptor in mice elevates age-associated anxiety and depressive-like behavior by altering dopamine metabolism [48]. The relationship was positive among younger subjects, but weakened as subjects aged [24]. It remains unclear what the logical basis is for this pattern, but it can be attributed to selection bias. A logical justification for this pattern is not clear, but it is identified that selection bias may be present. Most likely, older subjects with greater levels of depression and comorbidities refused to participate in the study.

Serum lipids and depression have been investigated, but so far the evidence has been inconsistent, and most studies have focused primarily on total cholesterol levels [49]. Depression was associated with a lower HDL cholesterol level [50]. Patients with bipolar depression had significantly higher levels of triglycerides (TG) than healthy controls [51]. The OR for low HDL cholesterol as well as hypertriglyceridemia in men suffering from severe depression was significantly higher, and the OR in women with hypertriglyceridemia was also significantly higher [52]. In addition, in contrast to people with remitted depression and healthy controls, those currently suffering from major depression have higher levels of TG and lower levels of HDL [53].

Depression and blood pressure have an inconsistent relationship. Low blood pressure and depression have been linked in some cross-sectional studies [54], while longitudinal studies concluded that depression predicted low blood pressure [55]. Low blood pressure, on the other hand, was a predictor of higher depression levels [56]. Several studies found that late-life depression and high blood pressure were related [57]. Hence, it would be good to study the Vascular Depression hypothesis [58], according to which certain geriatric depressive disorders are predisposed to, accelerate, or continue as a result of cardiovascular disease, such as high blood pressure.

The sex-related differences can be justified by leptin concentration. Based on the gender of the subjects, the concentration of serum leptin and depression had different relations. Women with depression had elevated leptin levels, but men did not [59]. In another study, serum levels of leptin were found to be high in all people with depressive symptoms, but higher in women who had depression than men with depressive symptoms [60].

In light of the diverse range of physical and psychosocial factors affecting obesity subtypes and depression, differences between the findings may have their roots in several factors. Other than gene-environment interactions [61], psychological factors also appear to have an impact on this relationship. Furthermore, this inconsistency may result from the diversity in the definition of MUHO due to the lack of universal agreement. A previous study involving three different definitions for metabolic health found that the association between excess weight and mood varied widely according to the definition of metabolic health [7]. Furthermore, the study designs or follow-up durations differed. Moreover, it is impossible to prove reverse causality or residual confounding from observational evidence even when obtained from a longitudinal study. So, there might be a relationship between abnormal metabolic condition and depression due to unmeasured risk behaviors such as poor diet or noncompliance with medical treatment [30].

Aside from mental challenges, obesity is also associated with disability and comorbidity problems, which can adversely affect one’s QoL. Only the physical health domain of the SF-36 index was associated with MetS and poor QoL in a cross-sectional study; as soon as BMI was controlled for, the relationship disappeared, indicating that BMI alone accounts for the relationship [6] proposing that the extent of metabolic abnormalities may not be linearly associated with such mental issues and QoL. Excess weight led to the greatest impairment in mobility in both men and women [62]. A lower HRQoL was related to the physical functioning feature in obese males and females [63, 64]. There is inconsistent evidence that metabolic health affects Euroqol-5 dimensions (EQ-5D); pain/discomfort showed a higher OR in those with MetS [65]. The male population with MetS had disturbances in usual activities, but the female population with MetS showed difficulties in all 5 aspects of EQ-5D [14]. Fatigue and excessive daytime sleepiness are also main symptoms associated with central obesity, and may negatively impact women’s HRQoL [66]. There may be some explanation for the lower HRQoL of women than men based on sex-different prevalence of obesity-induced comorbidities and health-related behaviors such as physical activity [22]. However, as revealed by a cross-sectional study [12], in which HRQoL were assessed using the EQ-5D questionnaire, physical aspect of HRQoL were lower among
metabolically unhealthy non-obese participants, suggesting that metabolic issues are more influential than excessive weight.

According to our knowledge, this is the first study to look systematically at the relationship between obesity phenotypes and mental health and HRQoL. However, this review is limited by the small number of researches. There are a multitude of outcome measurements reported across age groups and with a variety of genetic variations contributing to heterogeneity. The relation was not evaluated for secular direction since few studies examined the relationship longitudinally. It is therefore necessary to conduct large longitudinal cohort studies to clarify this association.

Conclusion
Overall, it is reasonable to conclude that when obesity occurs in conjunction with metabolic disturbances, its relationship with mental health issues and poor QoL is strengthened. In order to decrease the heavy burden of comorbid depression in obese individuals, we need to better understand the relationship between obesity phenotypes and mental health and HRQoL. These strategies may include pharmacological (such as anti-inflammatory medications and/or surgically-induced weight loss) or non-pharmacological interventions (such as weight loss programs and nutritional interventions with immunomodulatory effects) aimed at decreasing metabolic abnormalities and systemic inflammation in obese patients.

Acknowledgements
None.

Author contributions
BA, FH, and MV contributed to the design of the study, conducted the searches, screening, quality appraisal, data extraction, analysis, synthesis, drafted and edited the manuscript. SAM conducted the data extraction. FH and SB contributed to the design of the study, supported screening, and revised the manuscript. MV advised and revised the manuscript. MV has primary responsibility for final content. All authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent to publication
Not applicable.

Competing interests
The authors declare no competing interests.
20. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89.

21. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Oxford, 2000.

22. Truethmann J, Mensink GBM, Bosy-Westphal A, Hapke U, Scheidt-Nave C, Schienkewitz A. Physical health-related quality of life in relation to metabolic health and obesity among men and women in Germany. Health Qual Life Outcomes. 2017;15(1):122.

23. Delgado I, Huet L, Despert S, Beau C, Forester D, Ledaqueuel P, et al. Depressive symptoms in obesity: relative contribution of low-grade inflammation and metabolic health. Psychoneuroendocrinology. 2018;91:55–61.

24. Portugal-Nunes C, Reis J, Coelho A, Moreira PS, Castanho TC, Magalhaes R, et al. The association of metabolic dysfunction and mood across lifespan interact with the default mode network functional connectivity. Front Aging Neurosci. 2021;13:e61623.

25. Seo Y, Lee S, Ahn JS, Min S, Kim MH, Kim JY, et al. Association of metabolically healthy obesity and future depression: using national health insurance system data in Korea from 2009–2017. Int J Environ Res Public Health. 2020;18(1):63.

26. Imbimba L, Tess BH, Griepe RH, Fonseca MJM, Pereira AC, Diniz MF, et al. Metabolic status is not associated with job stress in individuals with obesity: the ELSA-Brasil baseline. Int Arch Occup Environ Health. 2021;94(4):639–46.

27. Yosaee S, Djafarian K, Esteghamati A, Motevalian A, Shidfar F, Tehrani-Doost M, et al. Depressive symptoms among metabolically healthy and unhealthy overweight/obese individuals: a comparative study. Med J Islam Repub Iran. 2018;32:95.

28. Hamer M, Bailey GD, Kivimaki M. Risk of future depression in people who are obese but metabolically healthy: the English longitudinal study of ageing. Mol Psychiatry. 2011;17(9):940–5.

29. Park H, Lee K. The relationship between metabolically healthy obesity and suicidal ideation. J Affect Disord. 2021;292:369–74.

30. Hinnouho GM, Singh-Manoux A, Gueguen A, Pell JP. Impact of metabolic comorbidity on the association between body mass index and health-related quality of life: a Scotland-wide cross-sectional study of 5,608 participants. BMC Public Health. 2012;12:143.

31. Amir P, Jalali-Farahani S, Rezaei M, Cheraghi L, Hosseinpanah F, Azizi F. Association of metabolic status with job stress in individuals with obesity: the ELSA-Brasil baseline. Int Arch Occup Environ Health. 2021;94(4):639–46.

32. Pan A, Keum N, Okereke OI, Sun Q, Kivimaki M, Rubin RR, et al. Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care. 2012;35(5):1171–80.

33. Renn BN, Feliciano L, Segal DL. The bidirectional relationship of depression and diabetes: a systematic review. Clin Psychol Rev. 2011;31(8):1239–46.

34. Gariepy G, Wang J, Lesage AD, Schmitz N. The longitudinal association from obesity to depression: results from the 12-year National Population Health Survey. Obesity (Silver Spring, Md). 2010;18(5):1033–8.

35. Zavala GA, Kolovos S, Chiariotto A, Bomses JE, Campos-Ponce M, Rosado JL, et al. Association between obesity and depressive symptoms in Mexican population. Soc Psychiatry Psychiatr Epidemiol. 2018;53(6):639–46.

36. Demirci H, Cinar Y, Bilgel N. Metabolic syndrome and depressive symptoms among workers: a systematic review and meta-analysis. Obes Rev. 2019;20(11):1557–68.

37. Kuk JL, Ardern CI. Age and sex differences in the clustering of metabolic syndrome factors: association with mortality risk. Diabetes Care. 2010;33(11):2457–61.

38. Ho RC, Nito M, Kua EH, Ng TP. Body mass index, waist circumference, waist-hip ratio and depressive symptoms in Chinese elderly: a population-based study. Int J Geriatr Psychiatry. 2008;23(4):401–8.

39. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiat. 2010;67(5):446–57.

40. Jacka FN, Cherbuin N, Anstey KJ, Buttenworth P. Dietary patterns and depressive symptoms over time: examining the relationships with socioeconomic position, health behaviours and cardiovascular risk. PLoS ONE. 2014;9(1):e87657.

41. Pearson S, Schmidt M, Patton G, Dwyer T, Blizzard L, O’atalah P, et al. Depression and insulin resistance: cross-sectional associations in young adults. Diabetes Care. 2010;33(5):1128–33.

42. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24(6):1069–78.

43. Kleinridders A, Cai W, Cappellucci L, Ghazarian A, Collins WR, Venberg SG, et al. Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proc Natl Acad Sci USA. 2015;112(11):3463–8.

44. Beydoun MA, Beydoun HA, Dore GA, Fanelli-Kuczmarski MT, Evans MK, Zonderman AB. Total serum cholesterol, atherogenic indices and their longitudinal association with depressive symptoms among US adults. Transl Psychiatry. 2015;5(3):e518.

45. Kim JM, Stewart R, Kim SW, Shin IS, Yang SJ, Yoon JS. Cholesterol and serotonin transporter polymorphism interactions in late-life depression. Neurobiol Aging. 2013;34(2):336–43.

46. Sagud M, Mihaljevic-Peles A, Pivac N, Jakovljevic M, Muck-Seler D. Lipid levels in female patients with affective disorders. Psychiatry Res. 2009;168(3):218–21.

47. Kim EY, Kim SH, Ha K, Lee HJ, Yoon DH, Ahn YM. Depression trajectories and the association with metabolic adversities among the middle-aged adults. J Affect Disord. 2015;188:14–21.

48. van Reedt Dortland AK, Giltay EJ, van Veen T, van Pelt J, Zitman FG, Penninx BW. Associations between serum lipids and major depressive disorder: results from the Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiatry. 2010;71(6):729–36.

49. Lenoir H, Lacombe JM, Dufouil C, Ducimetière P, Hanon O, Ritchie K, et al. Relationship between blood pressure and depression in the elderly. The three-city study. J Hypertens. 2008;26(9):1765–72.

50. Hildrum B, Myklesten A, Holmen J, Dahl AA. Effect of anxiety and depression on blood pressure: 11-year longitudinal population study. Br J Psychiatry. 2008;193(2):108–13.

51. Patelini S, Verderi-Taillefer MH, Geniste C, Bisserbe JC, Alpérovitch A. Low blood pressure and risk of depression in the elderly: a prospective community-based study. Br J Psychiatry. 2000;176:464–7.

52. Lavretsky H, Lessier IM, Wohl M, Miller BL. Relationship of age, age at onset, and sex to depression in older adults. Am J Geriatr Psychiatry. 1998;6(3):248–56.

53. Taylor WD, Aziznejad F, Alexopoulos GS. The vascular depression hypothesis: mechanisms linking vascular disease with depression. Mol Psychiatry. 2013;18(9):963–74.

54. Antonijevic IA, Murck H, Frieboes RM, Horn R, Brabant G, Steiger A. Depressive symptoms in obesity: relative contribution of low-grade inflammation and metabolic health. Psychoneuroendocrinology. 2018;91:55–61.

55. Piers D, Doumas K, Diamanti-Kandarakis E, Rebuffe-Scrive P, et al. Total serum cholesterol, atherogenic indices and their longitudinal association with depressive symptoms among US adults. Transl Psychiatry. 2015;5(3):e518.

56. Hadi-Amini M, Akhondi-Yakhchi Z, Montazeri A, Ziaeifar M, Khodadadi M, Zadzadeh S, et al. Association of serum lipids and major depressive disorder: results from the Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiatry. 2010;71(6):729–36.

57. Lenoir H, Lacombe JM, Dufouil C, Ducimetière P, Hanon O, Ritchie K, et al. Relationship between blood pressure and depression in the elderly. The three-city study. J Hypertens. 2008;26(9):1765–72.

58. Patelini S, Verderi-Taillefer MH, Geniste C, Bisserbe JC, Alpérovitch A. Low blood pressure and risk of depression in the elderly: a prospective community-based study. Br J Psychiatry. 2000;176:464–7.

59. Lavretsky H, Lessier IM, Wohl M, Miller BL. Relationship of age, age at onset, and sex to depression in older adults. Am J Geriatr Psychiatry. 1998;6(3):248–56.
62. Søltoft F, Hammer M, Kragh N. The association of body mass index and health-related quality of life in the general population: data from the 2003 Health Survey of England. Qual Life Res. 2009;18(10):1293–9.

63. Vasiljevic N, Ralevic S, Marinikovic J, Kocer N, Maksimovic M, Milosevic GS, et al. The assessment of health-related quality of life in relation to the body mass index value in the urban population of Belgrade. Health Qual Life Outcomes. 2008;6:106.

64. Huang IC, Frangakis C, Wu AW. The relationship of excess body weight and health-related quality of life: evidence from a population study in Taiwan. Int J Obes. 2006;30(8):1250–9.

65. Han JH, Park HS, Shin CJ, Chang HM, Yun KE, Cho SH, et al. Metabolic syndrome and quality of life (QOL) using generalised and obesity-specific QOL scales. Int J Clin Pract. 2009;63(5):735–41.

66. Vgontzas AN, Bixler EO, Chrousos GP. Obesity-related sleepiness and fatigue: the role of the stress system and cytokines. Ann N Y Acad Sci. 2006;1083:329–44.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.